News Column

Researchers from University of Ulsan Detail Findings in Docetaxel Therapy (Accurate sequential detection of primary tumor and metastatic lymphatics...

July 23, 2014



Researchers from University of Ulsan Detail Findings in Docetaxel Therapy (Accurate sequential detection of primary tumor and metastatic lymphatics using a temperature-induced phase transition nanoparticulate system)

By a News Reporter-Staff News Editor at Biotech Week -- A new study on Drugs and Therapies is now available. According to news reporting originating in Seoul, South Korea, by NewsRx journalists, research stated, "Primary tumor and tumor-associated metastatic lymphatics have emerged as new targets for anticancer therapy, given that these are difficult to treat using traditional chemotherapy. In this study, docetaxel-loaded Pluronic nanoparticles with Flamma™ (FPR-675, fluorescence molecular imaging dye; DTX/FPR-675 Pluronic NPs) were prepared using a temperature-induced phase transition for accurate detection of metastatic lymphatics."

The news reporters obtained a quote from the research from the University of Ulsan, "Significant accumulation was seen at the primary tumor and in metastatic lymph nodes within a short time. Particle size, maximum drug loading capacity, and drug encapsulation efficiency of the docetaxel-loaded Pluronic NPs were approximately 10.34 +/- 4.28 nm, 3.84 wt%, and 94 +/- 2.67 wt%, respectively. Lymphatic tracking after local and systemic delivery showed that DTX/FPR-675 Pluronic NPs were more potent in tumor-bearing mice than in normal mice, and excised mouse lymphatics showed stronger near-infrared fluorescence intensity on the tumor-bearing side than on the non-tumor- bearing side at 60 minutes post-injection. In vivo cytotoxicity and efficacy data for the NPs demonstrated that the systemically administered NPs caused little tissue damage and had minimal side effects in terms of slow renal excretion and prolonged circulation in tumor-bearing mice, and rapid renal excretion in non-tumor- bearing mice using an in vivo real-time near-infrared fluorescence imaging system."

According to the news reporters, the research concluded: "These results clearly indicate that docetaxel-loaded Pluronic NPs could provide a strategy to achieve effective cancer therapy by simultaneous delivery to primary tumors, tumor lymphatics, and tumor-associated metastatic lymphatics."

For more information on this research see: Accurate sequential detection of primary tumor and metastatic lymphatics using a temperature-induced phase transition nanoparticulate system. International Journal of Nanomedicine, 2014;9():2955-2965. International Journal of Nanomedicine can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Drugs and Therapies).

Our news correspondents report that additional information may be obtained by contacting K.S. Oh, University of Ulsan, Coll Med, Asan Med Center, Dept. of Otolaryngol, Seoul, South Korea. Additional authors for this research include J.Y. Yhee, D.E. Lee, K. Kim, I.C. Kwon, J.H. Seo, S.Y. Kim and S.H. Yuk.

Keywords for this news article include: Asia, Antineoplastics, Pharmaceuticals, Seoul, Docetaxel, South Korea, Mitotic Inhibitors, Drugs and Therapies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters